Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
- Conditions
- Interventions
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT00927186
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT00926380
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 419
- Registration Number
- NCT00896532
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 224
- Registration Number
- NCT00887354
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Thomas J. Schnitzer
- Target Recruit Count
- 12
- Registration Number
- NCT00826228
- Locations
- 🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States
Back Pain in Patients With Severe Osteoporosis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 650
- Registration Number
- NCT00761332
- Locations
- 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT00759772
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 20
- Registration Number
- NCT00754442
- Locations
- 🇺🇸
University of Maryland School of Medicine Division of Endocrinology, Baltimore, Maryland, United States
A Study for Teriparatide in Severe Osteoporosis
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 794
- Registration Number
- NCT00696644
- Locations
- 🇮🇹
For additional information regarding investigative sites for this study, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valeggio sul Mincio, Verona, Italy
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2008-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1637
- Registration Number
- NCT00670501
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.